References
- Maccio A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother 2012;13:2453–72.
- Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381–410.
- Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab 2012;16:153–66.
- Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, . Muscle wasting in cancer cachexia: Clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011;62:657–79.
- Warner TD, Mitchell JA. Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790–804.
- Smyth EM, Grosser T, Wang M, Yu Y, Fitzgerald GA. Prostanoids in health and disease. J Lipid Res 2009;50:S423–8.
- Solheim TS, Fearon KCH, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review. Acta Oncol 2013;52:6–17.
- Reid J, Hughes CM, Murray LJ, Parsons C, Cantwell MM. Non-steroidal anti-inflammatory drugs for treatment of cancer cachexia: A systematic review. Palliat Med Epub 2012 Mar 26.
- Lundholm K, Gelin J, Hyltander A, Lönnroth C, Sandström R, Svaninger G, et al.Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602–6.
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, . Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489–95.
- Christoffersen T, Guren TK, Spindler KLG, Dahl O, Lønning PØ, Gjertsen BT. Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. Eur J Pharmacol 2009;625:6–22.
- Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, . Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142: 531–43.
- Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: Progress and perspective. Cancer Lett 2004;215:1–20.
- Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181–93.
- Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 2007;369: 1603–13.
- Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518–27.
- Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302: 649–58.
- Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, . Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367: 1596–606.
- Davis TW, Zweifel BS, O’Neill JM, Heuvelman DM, Abegg AL, Hendrich TO, . Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Therap 2004;308:929–34.
- Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: Subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661–90.